DE69923439D1 - Lebendimpstoff gegen das humane immunodefizient-virus - Google Patents
Lebendimpstoff gegen das humane immunodefizient-virusInfo
- Publication number
- DE69923439D1 DE69923439D1 DE69923439T DE69923439T DE69923439D1 DE 69923439 D1 DE69923439 D1 DE 69923439D1 DE 69923439 T DE69923439 T DE 69923439T DE 69923439 T DE69923439 T DE 69923439T DE 69923439 D1 DE69923439 D1 DE 69923439D1
- Authority
- DE
- Germany
- Prior art keywords
- hiv
- mice
- proteins
- salmonella
- attenuated strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000700605 Viruses Species 0.000 title 1
- 241000699670 Mus sp. Species 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 241000607142 Salmonella Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 108700010908 HIV-1 proteins Proteins 0.000 abstract 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 abstract 1
- 102100034343 Integrase Human genes 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 230000002550 fecal effect Effects 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7394398P | 1998-02-06 | 1998-02-06 | |
| PCT/US1999/002503 WO1999039735A1 (en) | 1998-02-06 | 1999-02-04 | Live vaccine for human immunodeficiency virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69923439D1 true DE69923439D1 (de) | 2005-03-03 |
Family
ID=22116747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69923439T Expired - Fee Related DE69923439D1 (de) | 1998-02-06 | 1999-02-04 | Lebendimpstoff gegen das humane immunodefizient-virus |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1061950B1 (https=) |
| JP (1) | JP2002502827A (https=) |
| KR (1) | KR20010040618A (https=) |
| CN (1) | CN1216640C (https=) |
| AT (1) | ATE287727T1 (https=) |
| AU (1) | AU744730B2 (https=) |
| CA (1) | CA2320489A1 (https=) |
| DE (1) | DE69923439D1 (https=) |
| IL (1) | IL137680A0 (https=) |
| NZ (1) | NZ506093A (https=) |
| RU (1) | RU2223784C2 (https=) |
| WO (1) | WO1999039735A1 (https=) |
| ZA (1) | ZA99912B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2802426B1 (fr) * | 1999-12-15 | 2004-04-02 | Neovacs | Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires |
| CN1549726A (zh) * | 2000-07-31 | 2004-11-24 | 耶鲁大学 | 先天性免疫系统指导的疫苗 |
| KR100447530B1 (ko) * | 2001-08-14 | 2004-09-08 | 한국과학기술원 | ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법 |
| EP1670505B1 (en) | 2003-09-18 | 2012-11-14 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Dna promoters and anthrax vaccines |
| US8420102B2 (en) | 2006-03-07 | 2013-04-16 | Vaxinnate Corporation | Compositions that include hemagglutinin |
| CN101195823B (zh) * | 2007-11-20 | 2010-06-02 | 华东理工大学 | 细菌表面展示系统、方法及应用 |
| CN109207417A (zh) * | 2018-09-19 | 2019-01-15 | 湖北省农业科学院畜牧兽医研究所 | 鸡白痢-j亚群禽白血病双重平板凝集抗原及其制备方法 |
| CA3170478A1 (en) * | 2020-03-05 | 2021-09-10 | James E. Galen | Live salmonella typhi vectors engineered to express cancer protein antigens and methods of use thereof |
| WO2025063261A1 (ja) * | 2023-09-22 | 2025-03-27 | 塩野義製薬株式会社 | ウイルス由来タンパク質をコードするポリヌクレオチド |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757013A (en) * | 1983-07-25 | 1988-07-12 | The Research Foundation Of State University Of New York | Cloning vehicles for polypeptide expression in microbial hosts |
| WO1992011028A1 (en) * | 1990-12-19 | 1992-07-09 | Epitope, Inc. | Hiv reverse transcriptase vaccine |
| JP3100005B2 (ja) * | 1992-07-28 | 2000-10-16 | 雪印乳業株式会社 | ヒト免疫不全ウィルス感染・増殖抑制剤 |
| AU3958895A (en) * | 1994-10-18 | 1996-05-06 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
-
1999
- 1999-02-04 JP JP2000530232A patent/JP2002502827A/ja not_active Withdrawn
- 1999-02-04 NZ NZ506093A patent/NZ506093A/en unknown
- 1999-02-04 AU AU31801/99A patent/AU744730B2/en not_active Ceased
- 1999-02-04 KR KR1020007008489A patent/KR20010040618A/ko not_active Abandoned
- 1999-02-04 IL IL13768099A patent/IL137680A0/xx unknown
- 1999-02-04 WO PCT/US1999/002503 patent/WO1999039735A1/en not_active Ceased
- 1999-02-04 CN CN998027014A patent/CN1216640C/zh not_active Expired - Fee Related
- 1999-02-04 AT AT99913808T patent/ATE287727T1/de not_active IP Right Cessation
- 1999-02-04 RU RU2000123173/15A patent/RU2223784C2/ru not_active IP Right Cessation
- 1999-02-04 CA CA002320489A patent/CA2320489A1/en not_active Abandoned
- 1999-02-04 DE DE69923439T patent/DE69923439D1/de not_active Expired - Fee Related
- 1999-02-04 EP EP99913808A patent/EP1061950B1/en not_active Expired - Lifetime
- 1999-02-05 ZA ZA9900912A patent/ZA99912B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1061950B1 (en) | 2005-01-26 |
| WO1999039735A9 (en) | 2000-01-27 |
| RU2223784C2 (ru) | 2004-02-20 |
| KR20010040618A (ko) | 2001-05-15 |
| EP1061950A1 (en) | 2000-12-27 |
| EP1061950A4 (en) | 2001-12-05 |
| AU744730B2 (en) | 2002-02-28 |
| CN1216640C (zh) | 2005-08-31 |
| CN1290175A (zh) | 2001-04-04 |
| AU3180199A (en) | 1999-08-23 |
| JP2002502827A (ja) | 2002-01-29 |
| WO1999039735A1 (en) | 1999-08-12 |
| ZA99912B (en) | 2000-08-07 |
| IL137680A0 (en) | 2001-10-31 |
| NZ506093A (en) | 2003-08-29 |
| CA2320489A1 (en) | 1999-08-12 |
| ATE287727T1 (de) | 2005-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mayr et al. | Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs | |
| Plotkin | Correlates of protection induced by vaccination | |
| Estes et al. | Nonhuman primate models of human viral infections | |
| Letvin | Progress in the development of an HIV-1 vaccine | |
| ATE295895T1 (de) | Genetischer impfstoff gegen den immunschwäche virus | |
| Sharpe et al. | Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity | |
| Schmidt et al. | Chikungunya vaccine candidates: current landscape and future prospects | |
| Shata et al. | Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8+ T cells and antiviral protective immunity | |
| Flynn et al. | Feline leukaemia virus: protective immunity is mediated by virus‐specific cytotoxic T lymphocytes | |
| FR07C0020I2 (fr) | Proteines de capsides de virus du papillome hpv16 recombinees a auto-assemblage | |
| Sanz-Parra et al. | Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins. | |
| Masopust | Developing an HIV cytotoxic T‐lymphocyte vaccine: issues of CD8 T‐cell quantity, quality and location | |
| Stephenson et al. | First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1 | |
| Kawagishi et al. | Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses | |
| Perlman et al. | Middle East respiratory syndrome vaccines | |
| DE69923439D1 (de) | Lebendimpstoff gegen das humane immunodefizient-virus | |
| Martins et al. | What is the predictive value of animal models for vaccine efficacy in humans? Rigorous simian immunodeficiency virus vaccine trials can be instructive | |
| Yuan | Vaccine Efficacy Evaluation: The Gnotobiotic Pig Model | |
| Grant et al. | The B-cell response to foot-and-mouth-disease virus in cattle following vaccination and live-virus challenge | |
| Barthold | Research Complications and State of Knowledge | |
| Kumar et al. | Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses | |
| Majid et al. | Negligible effect of chicken cytokine IL-12 integration into recombinant fowlpox viruses expressing avian influenza virus neuraminidase N1 on host cellular immune responses | |
| Korioth-Schmitz et al. | Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity | |
| Tijhaar et al. | Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus | |
| Inchauspé et al. | Vaccination against hepatitis B and C: towards therapeutic application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |